



Immunotherapeutics for Treating Infectious Diseases and Beyond

Guest Editors:

Dr. Sneha Ratnapriya

Department of Medicine, Harvard
Medical School, Boston, MA, USA

Dr. Keerti Rawat

Brigham and Women's Hospital,
Harvard Medical School, Boston,
MA, USA

Dr. Yonatan Butbul Aviel

Department of Pediatrics and
Pediatric Rheumatology Service,
Ruth Children's Hospital,
Rambam Health Care Campus,
Haifa, Israel

Deadline for manuscript
submissions:

31 January 2025

Message from the Guest Editors

Dear Colleagues,

Immunotherapy or immune-based therapy has a long history of success in the treatment of a wide range of human diseases, including cancer and infectious, metabolic, and autoimmune diseases, serving as a promising substitute to chemotherapeutics. This strategy involves the use of biological and/or synthetic agents to modulate host immune responses toward the cure. New technological advancements have been made to enhance the effects of therapeutic antibodies by employing several modifications, such as antibody engineering (Fc engineering, glycoengineering), as well as developing human, humanized, chimeric, and bispecific antibodies, etc. Despite this, in recent years, functional limitations related to immunotherapeutics, including inadequate pharmacokinetics and compromised non-specific interactions within the immune system, have been revealed and these deficits indicate the need to perform additional in-depth research and more significant efforts in this direction.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

Journal Rank: JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com